Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution.
Buscarini
Elisabetta
E
Manfredi
Guido
G
Zambelli
Alessandro
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006439:Hemodynamics; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*; D016896:Treatment Outcome; D054079:Vascular Malformations / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab